Enliven Therapeutics, Inc. · NASDAQ:ELVN
Kunkel Lori Anne sold 10,000 Enliven Therapeutics, Inc. shares (Form 4)
Traded Jun 5, 2026 · Filed Jun 9, 2026
On Jun 5, 2026, Kunkel Lori Anne (Director) sold 10,000 Enliven Therapeutics, Inc. shares at an average US$34.54 for US$345K under a trading plan, leaving 51,884 shares. Filed Jun 9, 2026 (Form 4).
- Sold
- 10,000 shares
- Price
- US$34.54 average (US$34.28 to US$35.82)
- Value
- US$345K
- Holding after
- 51,884 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Common Stock | Sale | 7,779 | US$34.28 | 54,105 | Direct |
| Jun 5, 2026 | Common Stock | Sale | 1,867 | US$35.36 | 52,238 | Direct |
| Jun 5, 2026 | Common Stock | Sale | 354 | US$35.82 | 51,884 | Direct |
Source
Related
- Enliven Therapeutics, Inc.
- Kunkel Lori Anne
- Enliven Therapeutics, Inc. shareholders
- Form 4 · Kunkel Lori Anne · Jul 8, 2026
- Form 4 · Hohl Benjamin · Oct 21, 2026
- Form 4 · Collins Helen Louise · Oct 21, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Hohl Benjamin · Sep 21, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026